Shares in AnGes MG have risen in Tokyo after the Japanese bioventure firmed up the timing for the start of a long-planned pivotal clinical trial with its lead therapeutic candidate.
written on 10.02.2014
AnGes MG's HGF gene therapy finally set for Phase III start
